Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension of CBAF312A2201: long-term safety of BAF312 in relapsing multiple sclerosis
2009-014392-51Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind, single-arm trial of siponimod in multiple sclerosis (MS), sponsored by Novartis. Primary endpoint: Long-term safety of BAF312. Started Oct 2009; status: completed.
02
Drugs
siponimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2009-014392-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014392-51.